MicroRNA machinery in Parkinson's disease: a platform for neurodegenerative diseases

被引:16
|
作者
Saghazadeh, Amene [1 ,2 ]
Rezaei, Nima [1 ,2 ,3 ,4 ]
机构
[1] Univ Tehran Med Sci, Mol Immunol Res Ctr, Sch Med, Tehran, Iran
[2] Univ Tehran Med Sci, Dept Immunol, Sch Med, Tehran, Iran
[3] Univ Tehran Med Sci, Res Ctr Immunodeficiencies, Childrens Med Ctr, Tehran, Iran
[4] Universal Sci Educ & Res Network USERN, Tehran, Iran
关键词
microRNAs; Parkinson's disease; neurodegenerative diseases; inflammation; autophagy; apoptosis; oxidative stress; DEEP-BRAIN-STIMULATION; ALPHA-SYNUCLEIN EXPRESSION; SUBSTANTIA-NIGRA; STEM-CELLS; SUBTHALAMIC NUCLEUS; NEUROTROPHIC FACTOR; MEDIATED AUTOPHAGY; CONTAINING NEURONS; MIRNA-433; BINDING; DOPAMINE NEURONS;
D O I
10.1586/14737175.2015.1114886
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
MicroRNAs (miRNAs) are noncoding RNAs that recognize their protein-coding target genes and whereby subjugate them after transcription. Despite the infancy of this field of science, the role of miRNAs in neurodegeneration is well-acknowledged. This review was conducted to indicate that Parkinson's disease (PD) is not excluded from this rule. To this end, we evaluated the existing literature and arranged PD-associated miRNAs according to their mechanism of action, particularly apoptosis, autophagy, inflammation, mitochondrial dysfunction and oxidative stress. According to this arrangement, a majority of PD-associated miRNAs were indicated to influence autophagic/apoptotic pathways. We also categorized PD-associated miRNAs according to that they could exert detrimental or beneficial or both into three sets, activator, inhibitor, and double-edged, correspondingly. Considering this criterion, a majority of PD-associated miRNAs were included in the activator category. In addition, evidences from genetic association studies investigating genetic variants of or related to miRNAs in PD patients are presented. Finally, possible applications of the miRNA machinery in PD, including mechanistic networks, diagnostic, prognostic and therapeutic potentials, are discussed. But there may be additional miRNAs involved in the pathogenesis of PD which have hitherto remained unknown and thus further studies are needed to explore the issue and to extend this platform.
引用
收藏
页码:427 / 453
页数:27
相关论文
共 50 条
  • [21] Changes of Colonic Bacterial Composition in Parkinson's Disease and Other Neurodegenerative Diseases
    Gerhardt, Sara
    Mohajeri, M. Hasan
    NUTRIENTS, 2018, 10 (06)
  • [22] EMPATHY PROCESSES IN NEURODEGENERATIVE DISEASES: PRELIMINARY RESULTS IN PARKINSON'S DISEASE (PD)
    Narme, P.
    Krystkowiak, P.
    Roussel, M.
    Mouras, H.
    Godefroy, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2011, 18 : 415 - 415
  • [23] Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease
    Bayer, AU
    Keller, ON
    Ferrari, F
    Maag, KP
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 133 (01) : 135 - 137
  • [24] Effects of shikonin on neurodegenerative diseases (Alzheimer's disease and Parkinson's disease): a preliminary study in an animal model of both diseases
    Taniguchi, Taizo
    Yoshida, Lucia Satiko
    Shichiri, Hiroaki
    Watanabe, Aimi
    Takenokuchi, Mariko
    Kadoyama, Keiichi
    Miyamoto, Kazuhide
    Takano-Ohmuro, Hiromi
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2013, 121 : 143P - 143P
  • [25] Nanotechnology used for siRNA delivery for the treatment of neurodegenerative diseases: Focusing on Alzheimer's disease and Parkinson's disease
    Li, Yan
    Zhang, Jiahui
    Ma, Boqin
    Yu, Wenjun
    Xu, Meixia
    Luan, Weijing
    Yu, Qinglong
    Zhang, Li
    Rong, Rong
    Fu, Yuanlei
    Cao, Haiqiang
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2024, 666
  • [26] MicroRNA and lncRNA in Neurodegenerative Diseases
    Huang Wen-Tao
    Guo Xiang-Qian
    Dai Jia-Pei
    Chen Run-Sheng
    PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS, 2010, 37 (08) : 826 - 833
  • [27] Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease)
    Spuch, Carlos
    Navarro, Carmen
    JOURNAL OF DRUG DELIVERY, 2011, 2011
  • [28] Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis
    Devos, David
    Cabantchik, Z. Ioav
    Moreau, Caroline
    Danel, Veronique
    Mahoney-Sanchez, Laura
    Bouchaoui, Hind
    Gouel, Flore
    Rolland, Anne-Sophie
    Duce, James A.
    Devedjian, Jean-Christophe
    Cassereau, Julien
    Bost, Marie
    Abrial, Charlotte
    Muller, Jeanne
    Olivier, Audrey
    Le Masson, Gwendal
    Mathis, Stephane
    Djigo, Dieynaba
    Bonabaud, Sarah
    Deloire, Mathilde
    Genestet, Steeve
    Menanteau, Elsa
    Bourgeois, Pauline
    Lefilliatre, Mathilde
    Viader, Fausto
    Abrou, Mouloud
    Chavanne, Damien
    Bari, Rachida
    Guy, Nathalie
    Arondo, Sophia Sickout
    Rouvet, Sandrine
    Beauvais, Katell
    Aidan, Mathilde
    Madec, Olivier
    Danel-Brunaud, Veronique
    Tard, Celine
    Pleuvret, Marie
    Santraine, Valerie
    Moutarde, Julie
    Couratier, Philippe
    Lautrette, Geraldine
    Machat, Selma
    Penoty, Marie
    Villeneuve, Olivier
    Labetoulle, Clemence
    Catteau, Julie
    Bernard, Emilien
    Svahn, Juliette
    Neuillet, Camille
    Attarian, Shahram
    JOURNAL OF NEURAL TRANSMISSION, 2020, 127 (02) : 189 - 203
  • [29] Iron as a therapeutic target for neurodegenerative diseases (Parkinson's disease and amyotrophic lateral sclerosis)
    Devos, D.
    Moreau, C.
    FEBS OPEN BIO, 2018, 8 : 33 - 33
  • [30] Cell reprogramming and neuronal differentiation applied to neurodegenerative diseases: Focus on Parkinson's disease
    Wenker, Shirley D.
    Casalia, Mariana
    Cavaliere Candedo, Veronica
    Cruz Casabona, Juan
    Pitossi, Fernando J.
    FEBS LETTERS, 2015, 589 (22): : 3396 - 3406